Analysis of time to first COPD exacerbation and exacerbation rates
| Indacaterol 300 μg | Indacaterol 600 μg | Formoterol | Placebo | |
| Patients with a COPD exacerbation, n (%) | 133 (32.8) | 116 (29.3) | 126 (31.5) | 145 (36.3) |
| Event-free rate at month 12, % (95% CI) | 63.1 (58.1 to 68.1) | 66.7 (61.7 to 71.7) | 65.0 (60.0 to 70.0) | 57.0 (51.6 to 62.4) |
| HR vs placebo (95% CI) | 0.77 (0.606 to 0.975)* | 0.69 (0.538 to 0.882)* | 0.77 (0.605 to 0.981)* | |
| Rate of exacerbations per year | 0.60 | 0.57 | 0.56 | 0.74 |
| Rate ratio vs placebo (95% CI) | 0.82 (0.63 to 1.06) | 0.74 (0.56 to 0.97)* | 0.75 (0.58 to 0.99)* |
↵* p<0.05 vs placebo. Differences between indacaterol and formoterol not significant.
COPD, chronic obstructive pulmonary disease.